AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
fludeoxyglucose (18F) 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4455 | 105851-17-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Fludeoxyglucose F18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [18 F] FDG-6- phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F 18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F 18 transport and phosphorylation (expressed as the “lumped constant” ratio), Fludeoxyglucose F 18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F 18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F 18 reflect greater than normal rates of glucose metabolism.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CD,PRKDC,SIK2,TEK | 25 | |||
| kinase-selectivity-class | ACVRL1,AXL,CDK1,CDK2,CDK4,CHUK,DYRK1A,IRAK4,MAP2K6,MAP3K14,PDK1,PIK3CD,TGFBR1,ZAP70 | 14 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 19, 1994 | FDA | DOWNSTATE CLINCL | |
| July 5, 2005 | PMDA | Nihon Medi-Physics Co., Ltd. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cytokine release syndrome | 73.63 | 49.20 | 20 | 169 | 44507 | 42576639 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pulmonary microemboli | 61.20 | 45.39 | 6 | 264 | 28 | 110589001 |
| Cytokine release syndrome | 57.20 | 45.39 | 16 | 254 | 70290 | 110518739 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V09IX04 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS TUMOUR DETECTION Other diagnostic radiopharmaceuticals for tumour detection |
| FDA MoA | N0000000205 | Radiopharmaceutical Activity |
| FDA EPC | N0000177914 | Radioactive Diagnostic Agent |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Related Drugs by ATC class:
V09IX Other diagnostic radiopharmaceuticals for tumour detection 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Positron emission tomography | indication | 82918005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.1 | acidic |
| pKa2 | 12.31 | acidic |
| pKa3 | 14.0 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4024383 | VUID |
| N0000168559 | NUI |
| 63503-12-8 | SECONDARY_CAS_RN |
| 4024383 | VANDF |
| CHEBI:750387 | CHEBI |
| CHEMBL2030434 | ChEMBL_ID |
| CHEMBL497613 | ChEMBL_ID |
| DB09502 | DRUGBANK_ID |
| 450503 | PUBCHEM_CID |
| 1362737 | RXNORM |
| 15670 | MMSL |
| 194386 | MMSL |
| d04705 | MMSL |
| 003334 | NDDF |
| C0046056 | UMLSCUI |
| 6446 | INN_ID |
| 0Z5B2CJX4D | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| FludeoxyglucoseF18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13267-234 | INJECTION | 400 mCi | INTRAVENOUS | NDA | 16 sections |
| Fludeoxyglucose F18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24275-0185 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 16 sections |
| FLUDEOXYGLUCOSE F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24417-001 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 17 sections |
| FLUDEOXYGLUCOSE F-18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24450-647 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 25 sections |
| Fludeoxyglucose F-18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24468-001 | INJECTION | 500 mCi | INTRAVENOUS | ANDA | 22 sections |
| FludeoxyglucoseF 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24562-001 | INJECTION, SOLUTION | 300 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24562-003 | INJECTION, SOLUTION | 300 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29998-001 | INJECTION | 40 mCi | INTRAVENOUS | ANDA | 28 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40028-511 | INJECTION, SOLUTION | 200 mCi | INTRAVENOUS | ANDA | 23 sections |
| Fludeoxyglucose F-18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40098-101 | INJECTION, SOLUTION | 200 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49609-101 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 25 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52670-551 | INJECTION | 240 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F-18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52768-001 | INJECTION, SOLUTION | 500 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60055-334 | INJECTION, SOLUTION | 300 mCi | INTRAVENOUS | ANDA | 24 sections |
| FludeoxyglucoseF18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60215-411 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 16 sections |
| FludeoxyglucoseF18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62072-008 | INJECTION | 100 mCi | INTRAVENOUS | ANDA | 25 sections |
| Fludeoxyglucose F-18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65857-150 | INJECTION | 500 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67939-010 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 23 sections |
| Fludeoxyglucose F18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69587-001 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 25 sections |
| Fludeoxyglucose F18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69864-001 | INJECTION, SOLUTION | 0.30 Ci | INTRAVENOUS | ANDA | 17 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72634-001 | INJECTION | 0.50 Ci | INTRAVENOUS | ANDA | 22 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73410-003 | INJECTION | 20 mCi | INTRAVENOUS | ANDA | 24 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75913-647 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 16 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76318-334 | INJECTION, SOLUTION | 300 mCi | INTRAVENOUS | ANDA | 23 sections |
| Fludeoxyglucose F18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76326-001 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 16 sections |
| Fludeoxyglucose F18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76326-001 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 16 sections |
| Fludeoxyglucose F 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76376-618 | INJECTION, SOLUTION | 100 mCi | INTRAVENOUS | ANDA | 23 sections |
| FludeoxyglucoseF18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76451-118 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 26 sections |
| FLUDEOXYGLUCOSE F-18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 78714-001 | INJECTION | 300 mCi | INTRAVENOUS | ANDA | 24 sections |
| FludeoxyglucoseF 18 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81759-001 | INJECTION | 400 mCi | INTRAVENOUS | ANDA | 14 sections |